(MENAFN- GlobeNewsWire - Nasdaq) Company's year-end TULSA-PRO installed base stood at 78 systems; qualified sales pipeline grew to 97 new systems TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Profound ...
TORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...
Profound Medical Corp's TULSA-PRO system has the potential to disrupt the surgical treatment of prostate disease. The company is delivering solid growth in recurring and capital revenues. Despite high ...
TORONTO, June 04, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results